- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00201305
Gemcitabine Plus High-Dose 5-Fu/Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract
Prospective Phase II Randomized Trial-Weekly Gemcitabine Plus High-Dose 5-Fluorouracil/ Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
5-FU has been the mainstay of chemotherapeutic agents for gastrointestinal malignancies. The use of weekly 24-hour infusion of HDFL produces high clinical response in a variety of cancers, including colorectal, gastric and breast cancers, with minimal chemotherapy-related toxicity. Gemcitabine is a synthesized deoxycytidine analogue that is metabolized to dFdCTP in tumor cells and results in inhibition of DNA synthesis and depletion of normal cellular nucleotide pool. It has been shown to be active in the treatment of pancreatic cancer and non-small cell lung cancer. Since the biliary tract and the pancreas share a common embryonic origin and cancers from both sites are characterized by resistance to most chemotherapeutic agents, we postulate that gemcitabine may also be effective for cancer of the biliary tract. In our institution we have devised a regimen of weekly gemcitabine and 24-hour infusion of HDFL for patients with advanced or metastatic pancreatic adenocarcinoma. In 18 evaluable patients, 2 achieved a partial response and 3 minor response. The median duration of response was 4 months and the treatment-related toxicity was acceptable.
The eligibility criteria are patients with advanced or metastatic carcinoma of the biliary tract who are not candidates for curative surgical treatment; good performance status; no prior chemotherapy; clinical measurable tumor; good organ function and good compliance. Each cycle of chemotherapy consists of 4 weeks. On days 1, 8 and 15, gemcitabine will be given by 30-minute intravenous infusion and 5-FU and leucovorin by 24-hour continuous intravenous infusion. The dose of gemcitabine will be 1000 mg/m2. The doses of 5-FU will be 2000 mg/m2 and leucovorin, 300 mg/m2. Treatment will continue until disease progresses or prohibitive toxicity develops. For patients with complete response (CR), chemotherapy will continue for 3 additional courses after the documentation of CR. Estimated time for patient accrual is 3 years.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Histologically proven carcinoma of the biliary tract, including gallbladder carcinoma and cholangiocarcinoma. The disease should be either locally advanced to the extent that curative surgery is impossible or with documented distant metastasis.
- Bi-dimensionally measurable disease by physical examination or image study (roentgenogram or computed tomography (CT) scan).
- Age > 18 years. For patients older than 70 years of age, detailed evaluation of the organ function reserves must be done before enrollment unto protocol treatment.
- Karnofsky performance status> 60%
- Adequate bone marrow reserves, defined as white blood cell (WBC)>4,000/ml, absolute neutrophil count (ANC)> 1,500/ml, platelet> 150,000/ml.
- Liver transaminases <5 times upper normal limits; total bilirubin <3 mg/dl; serum creatinine < 1.5 mg/dl
- Serum triglyceride level >70 mg/dl
- No prior cytotoxic chemotherapy. Previous radiotherapy is allowed if the treatment was completed at least 6 weeks before the enrollment onto this study.
- Patients of childbearing age should have effective contraception during the study period.
- All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional guidelines.
Exclusion criteria:
- Patients who are receiving concurrent radiotherapy, chemotherapy or other experimental therapy.
- Patients who refuse port-A catheter implantation
- Patients with brain or leptomeningeal metastases.
- Patients who have significant cardiac arrhythmia or acute myocardial infarction within 6 months before entry.
- Patients who have major systemic diseases that the attending physicians considered inappropriate for systemic chemotherapy.
- Life expectancy less than 2 months.
- Pregnant or nursing women may not participate. Women or men with reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
- Patients who have previous malignancy except for the following: adequately treated basal cell or squamous cell skin cancers, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any cancer from which the patient has been disease-free for 5 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To determine the response rate of weekly gemcitabine plus high-dose 5-FU/leucovorin chemotherapy for patients with advanced or metastatic biliary tract cancer.
|
Secondary Outcome Measures
Outcome Measure |
---|
To determine:
|
1.Toxicity profile of gemcitabine plus high-dose 5-FU/leucovorin chemotherapy for advanced or metastatic biliary tract cancer.
|
2.Time to disease progression
|
3.Overall survival
|
4.Quality of life
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Ann-Li Cheng, PHD, National Taiwan University Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Biliary Tract Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Micronutrients
- Vitamins
- Antidotes
- Vitamin B Complex
- Gemcitabine
- Leucovorin
Other Study ID Numbers
- T3202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biliary Tract Disease
-
Queen's UniversityCompletedBiliary Disease | ERCP | Biliary Disease TractCanada
-
Emory UniversityCompletedBiliary Tract DiseaseUnited States
-
University of FloridaCompletedBiliary Tract DiseaseUnited States
-
Qi-Yong LiCompletedBiliary Diseases | Pancreas DiseasesChina
-
Hospital Universitario Dr. Jose E. GonzalezRecruiting
-
Diskapi Yildirim Beyazit Education and Research...Unknown
-
University of FloridaCompletedPancreas Disease | Biliary DiseaseUnited States
-
University of CalgaryRecruitingPancreatic Diseases | Biliary DiseaseCanada
-
Fundacion Miguel ServetComplejo Hospitalario de NavarraCompletedPancreatic Diseases | Biliary DiseaseSpain
-
Huiwu XingCompletedLiver and Biliary Tract Disorders in Duration of Pregnancy | Other End-stage Liver Diseases in ChildrenChina
Clinical Trials on Gemcitabine+5FU+Leucovorin
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsUnknownPancreatic CancerTaiwan
-
Haruhiko FukudaMinistry of Health, Labour and Welfare, JapanCompletedColorectal NeoplasmsJapan
-
Zealand University HospitalRecruitingIntestinal Neoplasms | Colorectal Cancer | Rectal Cancer | Rectal Neoplasms | Colorectal Neoplasm | Chemotherapy Effect | Intestinal DiseaseDenmark
-
Marks, John, M.D.TerminatedRectal NeoplasmsUnited States
-
AHS Cancer Control AlbertaUnknown
-
Seoul National University Bundang HospitalCompletedBiliary Cancer MetastaticKorea, Republic of
-
PfizerCompletedColorectal NeoplasmsCanada, United States, France, Poland, Italy, Spain, Korea, Republic of, Japan
-
Novartis PharmaceuticalsActive, not recruitingMetastatic Colorectal CancerCanada, Taiwan, Belgium, Germany, Spain, Italy, Czechia, Switzerland, Australia, United States, Japan, Singapore, United Kingdom, France, Israel, Hong Kong, Korea, Republic of
-
Institut du Cancer de Montpellier - Val d'AurelleCompletedMetastatic Pancreatic AdenocarcinomaFrance
-
BioLineRx, Ltd.Merck Sharp & Dohme LLCCompletedMetastatic Pancreatic AdenocarcinomaUnited States, Israel, Korea, Republic of, Spain